New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
06:03 EDTIRIXIRIDEX announces final results of its tender offer
IRIDEX Corporation announced the final results of its tender offer to purchase up to 487,500 shares of its common stock at a purchase price of $4.10 per share, which expired at 5:00 p.m., New York City time, on Friday, December 7. IRIDEX has accepted for payment an aggregate of 487,500 shares of its common stock, including all "odd lots" properly tendered, at a purchase price of $4.10 per share, for a total cost of approximately $2M. These shares represent approximately 5.5% of IRIDEX's currently issued and outstanding shares of common stock. Based on the final count by Computershare Inc., the depositary for the tender offer, 1.43M shares of IRIDEX common stock were properly tendered and not withdrawn, excluding any conditional tenders that were not accepted due to the specified condition not being satisfied. IRIDEX has been informed by the depositary that, after giving effect to the priority for "odd lots," the final pro-ration factor is approximately 32.9%. The depositary will promptly pay for the shares accepted for purchase and will return all other shares tendered.
News For IRIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 17, 2015
06:33 EDTIRIXIRIDEX announces first commercial sales of Cyclo G6 glaucoma laser systems
IRIDEX announced the first commercial sales of its new Cyclo G6 laser system, designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma dedicated laser along with a family of single use probes, including the newly patented MicroPulse P3 disposable. Glaucoma is an eye disease that causes damage to the optic nerve, which carries images from the retina to the brain. In glaucoma, heightened eye pressure can lead to progressive damage of the delicate nerve fibers of the optic nerve. The Cyclo G6 offers repeatable and minimally invasive approaches to slowing the progress of the disease.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use